This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Dow Today: Johnson & Johnson (JNJ) Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Links.

The
Dow Jones Industrial Average (
^DJI) is trading down 62.0 points (-0.4%) at 15,456 as of Wednesday, Aug 7, 2013, 1:35 p.m. ET. During this time, 257.3 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 578.4 million. The NYSE advances/declines ratio sits at 925 issues advancing vs. 2,034 declining with 101 unchanged.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is
Johnson & Johnson (NYSE:
JNJ), which is lagging the broader Dow index with a 14-cent decline (-0.1%) bringing the stock to $93.67. This single loss is lowering the Dow Jones Industrial Average by 1.06 points or roughly accounting for 1.7% of the Dow's overall loss. Volume for Johnson & Johnson currently sits at 5.9 million shares traded vs. an average daily trading volume of 9.9 million shares.

Johnson & Johnson has a market cap of $264.34 billion and is part of the health care sector and drugs industry. Shares are up 33.8% year to date as of Tuesday's close. The stock's dividend yield sits at 2.8%.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.

TheStreet Ratings rates Johnson & Johnson as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.